Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
暂无分享,去创建一个
R. Weiss | A. Hittelman | Robert M. Weiss | Darryl T. Martin | W. Mark Saltzman | M. Wheeler | Jill M. Steinbach | S. Shimizu | W. Mark Saltzman | Shogo Shimizu | Jingchun Liu | Hristos Z. Kaimakliotis | Marcia A. Wheeler | Adam B. Hittelman | H. Kaimakliotis | Jingchun Liu | Shogo Shimizu
[1] Matthew E Falagas,et al. Interstitial cystitis: an unsolved enigma. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[2] Christopher J. Cheng,et al. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. , 2011, Biomaterials.
[3] W. Mark Saltzman,et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.
[4] P. Sado,et al. Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.
[5] W. Shi,et al. Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. , 2010, Acta biochimica et biophysica Sinica.
[6] JaneR . Taylor,et al. The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats , 2010, Brain Research.
[7] P. Fong,et al. Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidism. , 2005, Journal of pediatric surgery.
[8] W. Sessa,et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo , 2003, Nature Medicine.
[9] C. C. Harness,et al. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. , 2005, Biomaterials.
[10] Christopher J. Cheng,et al. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[11] M. Chancellor,et al. State of the art in intravesical therapy for lower urinary tract symptoms. , 2010, Reviews in urology.
[12] M. Behlke. Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.
[13] G. Krissansen,et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.
[14] C. Lundberg,et al. FACS binding assay for analysing GDNF interactions , 2013, Journal of Neuroscience Methods.
[15] A. Prochiantz,et al. Penetratin story: an overview. , 2011, Methods in molecular biology.
[16] P. Opanasopit,et al. Chitosan-Mediated siRNA Delivery In Vitro: Effect of Polymer Molecular Weight, Concentration and Salt Forms , 2010, AAPS PharmSciTech.
[17] Se-Kwon Kim. Chitin, chitosan, oligosaccharides and their derivatives: biological activities and applications. , 2010 .
[18] Jun Jie Wang,et al. Recent advances of chitosan nanoparticles as drug carriers , 2011, International journal of nanomedicine.
[19] M. Bogataj,et al. Permeability of pig urinary bladder wall: time and concentration dependent effect of chitosan. , 2006, Biological & pharmaceutical bulletin.
[20] P. Opanasopit,et al. Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. , 2008, International journal of pharmaceutics.
[21] S A Lewis,et al. Everything you wanted to know about the bladder epithelium but were afraid to ask. , 2000, American journal of physiology. Renal physiology.
[22] Yen Cu,et al. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. , 2009, Molecular pharmaceutics.
[23] Joonyoung Park,et al. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. , 2012, Molecular pharmaceutics.
[24] Lisbeth Illum,et al. Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2) , 1994, Pharmaceutical Research.
[25] Leaf Huang,et al. Recent advances in intravesical drug/gene delivery. , 2006, Molecular pharmaceutics.
[26] N. Rioux-Leclercq,et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. , 2004, The Journal of urology.
[27] M. Tabrizian,et al. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery , 2010, Expert opinion on drug delivery.
[28] W. Saltzman,et al. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. , 2012, Biomaterials.
[29] S. Mitragotri,et al. Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry. , 2010, Macromolecular rapid communications.
[30] R. Banerjee,et al. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[31] E. Wood,et al. Effect of Chitosan on Epithelial Cell Tight Junctions , 2004, Pharmaceutical Research.
[32] Gunnar P. H. Dietz,et al. Delivery of bioactive molecules into the cell: the Trojan horse approach , 2004, Molecular and Cellular Neuroscience.
[33] H. Wong,et al. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. , 2011, Biomaterials.
[34] V. Dodane,et al. Effect of chitosan on epithelial permeability and structure. , 1999, International journal of pharmaceutics.
[35] C. Remuñán-López,et al. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.
[36] R. Kiessling,et al. Is survivin the potential Achilles' heel of cancer? , 2011, Advances in cancer research.
[37] M. Buschmann,et al. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. , 2006, Biomaterials.
[38] R. Weiss,et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, New England Journal of Medicine.
[39] I. Zuhorn,et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.
[40] P. Artursson,et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers , 2004, Gene Therapy.
[41] E. Denkbaş,et al. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. , 2002, International journal of pharmaceutics.
[42] M. Wirth,et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. , 2008, International journal of oncology.
[43] P. Glazer,et al. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[44] W. Saltzman,et al. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.
[45] G. Nikiforidis,et al. Interstitial cystitis: bladder training with intravesical oxybutynin. , 2000, The Journal of urology.
[46] R. Weiss,et al. Urine detection of survivin and diagnosis of bladder cancer. , 2001, JAMA.
[47] Stephen P. Fox,et al. Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies , 2004, Journal of drug targeting.
[48] M. Chancellor,et al. New frontiers in intravesical therapies and drug delivery. , 2006, European urology.